New “First” Program: Six Months of Free Lab Space for Eligible First-Time Biotech Founders >
Apply for Residency
Apply for Residency
Apply for Residency
Apply for Residency
Apply for Residency

Search

Vedanta Biosciences Closes $50 Million Financing to Advance Microbiome Therapeutics

Pinteon Therapeutics $12.03 million Fundraising

EnBiotix to Collaborate with Mayo Clinic on Engineered Phage Program

Elanco, EnBiotix Establish Collaboration Exploring Engineered Phage Technology

Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR087 in Patients with Relapsed/Refractory B-cell Lymphoma

Amgen Opens Nomination Process for LabCentral Residency

Read More

Vedanta Biosciences Granted U.S. Patent Broadly Covering Pharmaceutical Compositions for Microbiome Therapeutics Based on Bacterial Consortia

Bristol-Myers Squibb Awards First “Golden Tickets” for LabCentral to PanTher, Suono Bio

Read More

Cyteir Therapeutics Presents Preclinical Data Validating RAD51-AID as a Novel Target for Cancer Treatment at American Association of Cancer Research Annual Meeting

FierceBiotech names Fulcrum Therapeutics as one of its “Fierce 15” Biotech Companies of 2016